BC
EGRX

Barrett & Company’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Barrett & Company’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$524 – 630
2024
Q1 		$524 Hold
100
– – ﹤0.01% 592
2023
Q4 		$523 Hold
100
– – ﹤0.01% 583
2023
Q3 		$1.58K Hold
100
– – ﹤0.01% 558
2023
Q2 		$1.94K Hold
100
– – ﹤0.01% 531
2023
Q1 		$2.84K Hold
100
– – ﹤0.01% 486
2022
Q4 		$2.92K Hold
100
– – ﹤0.01% 488
2022
Q3 		$2.92K Buy
+100
New +$3.67K ﹤0.01% 488

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barrett & Company's EGRX Position: Q2 2024 in Review

Barrett & Company sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 100 shares — an estimated $524 sold.

Barrett & Company first reported a position in EGRX in Q3 2022 and held it in 7 quarters. The position peaked at $2.92K in Q4 2022. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Barrett & Company reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Barrett & Company sold 100 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $524.
  • Barrett & Company first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2022 and held it in 7 quarters.
  • Barrett & Company's Eagle Pharmaceuticals, Inc. position peaked at $2.92K in Q4 2022.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Barrett & Company's 13F filing for Q2 2024, filed 25 Jul 2024.